Janet Nicholson

Company: Boehringer Ingelheim

Job title: Global Asset Lead, CNS Diseases, Translational Medicine

Seminars:

Beyond DSM: Innovating a Symptom Domain-Based Biomarker Approach to Translate More Precise Targets into Early Clinical Development 2:15 pm

Deciphering the neurobiology underlying symptom domains such as impulsivity and cognition Applying this knowledge to identify subtype-specific targets for symptom domains across indications Translating these new targets into the early clinical spaceRead more

day: Day One Track B PM

Enhancing the Selectivity, Sensitivity & Predictive Validity of Animal Models to Successfully Translate Novel Antidepressant, Antipsychotic & Anxiolytic Therapeutics 1:01 pm

With a pressing need for in vivo assays that more accurately predict the effects of antidepressants, antipsychotics and anxiolytics in humans, join this collaborative workshop to benchmark new strategies, from recreating exact phenotypes to optimizing dose selection, to bridge the translational gap. Highlights Include: Leveraging advancements in systems neuroscience: which animal behaviours are meaningful indicators…Read more

day: Workshop Day